Alzheimer's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Alzheimer's Disease, including details on diagnosis, memory loss, heredity, treatment, medication.

Volume 2 (2005), Issue 2 (February)

1. Strain experienced by caregivers of dementia patients receiving palliative care: findings from the Palliative Excellence in Alzheimer Care Efforts (PEACE) Program.
   J Palliat Med, 7(6): 797-807. [Abstract] [Full-text]
2. Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer's disease.
   Biochemistry, 44(5): 1690-700. [Abstract] [Full-text]
3. Interaction of Tau with Fe65 links tau to APP.
   Neurobiol Dis, 18(2): 399-408. [Abstract] [Full-text]
4. Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology.
   Neurobiol Dis, 18(2): 390-8. [Abstract] [Full-text]
5. Expression of mitochondrial genes and transcription estimation in different brain areas in Alzheimer's disease patients.
   Neurobiol Dis, 18(2): 296-304. [Abstract] [Full-text]
6. alpha-Internexin immunoreactivity reflects variable neuronal vulnerability in Alzheimer's disease and supports the role of the beta-amyloid plaques in inducing neuronal injury.
   Neurobiol Dis, 18(2): 286-95. [Abstract] [Full-text]
7. Retrograde amnesia for semantic information in Alzheimer's disease.
   J Int Neuropsychol Soc, 11(1): 40-8. [Abstract] [Full-text]
8. Differential effects of Alzheimer's disease and Huntington's disease on the performance of mental rotation.
   J Int Neuropsychol Soc, 11(1): 30-9. [Abstract] [Full-text]
9. Fast decay of iconic memory in observers with mild cognitive impairments.
   Proc Natl Acad Sci U S A, 102(5): 1797-802. [Abstract] [Full-text]
10. Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study.
    Am J Med Genet B Neuropsychiatr Genet, 132(1): 5-8. [Abstract] [Full-text]
11. No association of a non-synonymous PLAU polymorphism with Alzheimer's disease and disease-related traits.
    Am J Med Genet B Neuropsychiatr Genet, 132(1): 21-3. [Abstract] [Full-text]
12. Linkage to chromosome 14q in Alzheimer's disease (AD) patients without psychotic symptoms.
    Am J Med Genet B Neuropsychiatr Genet, 132(1): 9-13. [Abstract] [Full-text]
13. APOE and other loci affect age-at-onset in Alzheimer's disease families with PS2 mutation.
    Am J Med Genet B Neuropsychiatr Genet, 132(1): 14-20. [Abstract] [Full-text]
14. Pisa syndrome in a cohort of Alzheimer's disease patients.
    Acta Neurol Scand, 111(3): 199-201. [Abstract] [Full-text]
15. CERAD test performances in amnestic mild cognitive impairment and Alzheimer's disease.
    Acta Neurol Scand, 111(3): 172-9. [Abstract] [Full-text]
16. Predictors of use of services among dementia caregivers.
    West J Nurs Res, 27(2): 126-40; discussion 141-7. [Abstract] [Full-text]
17. Enhanced stimulus contrast normalizes visual processing of rapidly presented letters in Alzheimer's disease.
    Vision Res, 45(8): 1013-20. [Abstract] [Full-text]
18. Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging.
    Am J Med, 118(2): 161-7. [Abstract] [Full-text]
19. Thinking the unthinkable: Alzheimer's, Creutzfeldt-Jakob and Mad Cow disease: the age-related reemergence of virulent, foodborne, bovine tuberculosis or losing your mind for the sake of a shake or burger.
    Med Hypotheses, 64(4): 699-705. [Abstract] [Full-text]
20. Efficacy of anti-Abeta antibody isotypes used for intracerebroventricular immunization in TgCRND8.
    Neurosci Lett, 375(3): 143-7. [Abstract] [Full-text]
21. The role of soluble intercellular adhesion molecules in neurodegenerative disorders.
    J Neurol Sci, 228(2): 129-35. [Abstract] [Full-text]
22. The practice of obtaining approval from medical research ethics committees: a comparison within 12 European countries for a descriptive study on acetylcholinesterase inhibitors in Alzheimer's dementia.
    Eur J Neurol, 12(3): 212-7. [Abstract] [Full-text]
23. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease.
    J Biol Chem, 280(6): 4079-88. [Abstract] [Full-text]
24. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells.
    J Biol Chem, 280(5): 3628-35. [Abstract] [Full-text]
25. Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease.
    Neurology, 64(3): 509-13. [Abstract] [Full-text]
26. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease.
    Neurology, 64(3): 501-8. [Abstract] [Full-text]
27. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center.
    Neurology, 64(3): 494-500. [Abstract] [Full-text]
28. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study.
    Arch Gen Psychiatry, 62(2): 217-24. [Abstract] [Full-text]
29. High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques.
    Exp Neurol, 192(1): 215-25. [Abstract] [Full-text]
30. Efficient radiosynthesis of carbon-11 labelled uncharged Thioflavin T derivatives using [11C]methyl triflate for beta-amyloid imaging in Alzheimer's Disease with PET.
    Appl Radiat Isot, 62(4): 591-5. [Abstract] [Full-text]
31. Attention and executive control predict Alzheimer disease in late life: results from the Berlin Aging Study (BASE).
    Am J Geriatr Psychiatry, 13(2): 134-41. [Abstract] [Full-text]
32. Relationship between body height and dementia.
    Am J Geriatr Psychiatry, 13(2): 116-23. [Abstract] [Full-text]
33. Regional cerebral metabolism in early Alzheimer's disease with clinically significant apathy or depression.
    Biol Psychiatry, 57(4): 412-21. [Abstract] [Full-text]
34. Detecting depression in Alzheimer's disease: evaluation of four different scales.
    Arch Clin Neuropsychol, 20(2): 271-6. [Abstract] [Full-text]
35. Assessing motor and cognitive regulation in AD, MCI, and controls using the Behavioral Dyscontrol Scale.
    Arch Clin Neuropsychol, 20(2): 183-9. [Abstract] [Full-text]
36. Sleep and circadian abnormalities in a transgenic mouse model of Alzheimer's disease: a role for cholinergic transmission.
    Neuroscience, 131(2): 375-85. [Abstract] [Full-text]
37. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders.
    Neurobiol Aging, 26(5): 645-54. [Abstract] [Full-text]
38. apoE isoforms and measures of anxiety in probable AD patients and Apoe-/- mice.
    Neurobiol Aging, 26(5): 637-43. [Abstract] [Full-text]
39. Altered p59Fyn kinase expression accompanies disease progression in Alzheimer's disease: implications for its functional role.
    Neurobiol Aging, 26(5): 625-35. [Abstract] [Full-text]
40. Altered transcriptional regulators in response to serum in immortalized lymphocytes from Alzheimer's disease patients.
    Neurobiol Aging, 26(5): 615-24. [Abstract] [Full-text]
41. Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases.
    Neurobiol Aging, 26(5): 587-95. [Abstract] [Full-text]
42. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients.
    Neurobiol Aging, 26(5): 567-73. [Abstract] [Full-text]
43. Focused attention deficits in patients with Alzheimer's disease and mild cognitive impairment.
    Brain Cogn, 57(2): 127-30. [Abstract] [Full-text]
44. Influence of education on the pattern of cognitive deterioration in AD patients: the cognitive reserve hypothesis.
    Brain Cogn, 57(2): 120-6. [Abstract] [Full-text]
45. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease.
    Neuropsychologia, 43(3): 442-9. [Abstract] [Full-text]
46. Coagulation and inflammatory markers in Alzheimer's and vascular dementia.
    Int J Clin Pract, 59(1): 52-7. [Abstract] [Full-text]
47. Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies.
    Acta Neuropathol (Berl), 109(1): 25-31. [Abstract] [Full-text]
48. Association analysis of apolipoprotein E genotype and risk of depressive symptoms in Alzheimer's disease.
    Dement Geriatr Cogn Disord, 19(2): 154-7. [Abstract] [Full-text]
49. Autonomic function assessed by heart rate variability is normal in Alzheimer's disease and vascular dementia.
    Dement Geriatr Cogn Disord, 19(2): 140-4. [Abstract] [Full-text]
50. Plasma levels of antioxidants are not associated with Alzheimer's disease or cognitive decline.
    Dement Geriatr Cogn Disord, 19(2): 134-9. [Abstract] [Full-text]
51. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
    Dement Geriatr Cogn Disord, 19(2): 126-33. [Abstract] [Full-text]
52. Estrogen-metabolizing gene COMT polymorphism synergistic APOE epsilon4 allele increases the risk of Alzheimer disease.
    Dement Geriatr Cogn Disord, 19(2): 120-5. [Abstract] [Full-text]
53. Predictive accuracy of MCI subtypes for Alzheimer's disease and vascular dementia in subjects with mild cognitive impairment: a 2-year follow-up study.
    Dement Geriatr Cogn Disord, 19(2): 113-9. [Abstract] [Full-text]
54. Increased alpha 7 nicotinic acetylcholine receptor protein levels in Alzheimer's disease patients.
    Dement Geriatr Cogn Disord, 19(2): 106-12. [Abstract] [Full-text]
55. Occurrence of cognitive impairment and dementia after the age of 60: a population-based study from Northern Italy.
    Dement Geriatr Cogn Disord, 19(2): 97-105. [Abstract] [Full-text]
56. Executive function impairment in community elderly subjects with questionable dementia.
    Dement Geriatr Cogn Disord, 19(2): 86-90. [Abstract] [Full-text]
57. Responsiveness of the quality of life in late-stage dementia scale to psychotropic drug treatment in late-stage dementia.
    Dement Geriatr Cogn Disord, 19(2): 82-5. [Abstract] [Full-text]
58. Semantic memory impairment in the earliest phases of Alzheimer's disease.
    Dement Geriatr Cogn Disord, 19(2): 75-81. [Abstract] [Full-text]
59. Correlation of entorhinal amyloid with memory in Alzheimer's and vascular but not Lewy body dementia.
    Dement Geriatr Cogn Disord, 19(2): 57-60. [Abstract] [Full-text]
60. Use of the QOL-AD for measuring quality of life in people with severe dementia--the LASER-AD study.
    Age Ageing, 34(2): 130-5. [Abstract] [Full-text]
61. Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor.
    J Am Chem Soc, 127(7): 2264-71. [Abstract] [Full-text]
62. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease.
    Proc Natl Acad Sci U S A, 102(7): 2273-6. [Abstract] [Full-text]
63. Nutritional and cognitive relationships and long-term mortality in patients with various dementia disorders.
    Age Ageing, 34(2): 136-41. [Abstract] [Full-text]
64. Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease.
    J Neurol Neurosurg Psychiatry, 76(3): 320-4. [Abstract] [Full-text]
65. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.
    J Neurol Neurosurg Psychiatry, 76(3): 315-9. [Abstract] [Full-text]
66. Differing neuropsychological and neuroanatomical correlates of abnormal reading in early-stage semantic dementia and dementia of the Alzheimer type.
    Neuropsychologia, 43(6): 833-46. [Abstract] [Full-text]
67. Apolipoprotein E and category fluency: evidence for reduced semantic access in healthy normal controls at risk for developing Alzheimer's disease.
    Neuropsychologia, 43(4): 647-58. [Abstract] [Full-text]
68. Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'.
    Int J Geriatr Psychiatry, 20(2): 119-27. [Abstract] [Full-text]
69. Biomarkers for apoptosis in Alzheimer's disease.
    Int J Geriatr Psychiatry, 20(2): 101-5. [Abstract] [Full-text]
70. Predictors of high level of burden and distress in caregivers of demented patients: results of an Italian multicenter study.
    Int J Geriatr Psychiatry, 20(2): 168-74. [Abstract] [Full-text]
71. Object naming and semantic fluency among individuals with genetic risk for Alzheimer's disease.
    Int J Geriatr Psychiatry, 20(2): 128-36. [Abstract] [Full-text]
72. Social distance towards a person with Alzheimer's disease.
    Int J Geriatr Psychiatry, 20(2): 182-8. [Abstract] [Full-text]
73. Oxidative state in platelets and erythrocytes in aging and Alzheimer's disease.
    Neurobiol Aging, 26(6): 857-64. [Abstract] [Full-text]
74. Inhibition of Alzheimer's amyloid-beta peptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin.
    Neurobiol Aging, 26(6): 849-55. [Abstract] [Full-text]
75. Mitochondrial function in fibroblasts with aging in culture and/or Alzheimer's disease.
    Neurobiol Aging, 26(6): 839-48. [Abstract] [Full-text]
76. Enhanced GM1 ganglioside catabolism in cultured fibroblasts from Alzheimer patients.
    Neurobiol Aging, 26(6): 833-8. [Abstract] [Full-text]
77. Fibroblast glutamate transport in aging and in AD: correlations with disease severity.
    Neurobiol Aging, 26(6): 825-32. [Abstract] [Full-text]
78. Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain.
    Neurobiol Aging, 26(6): 795-802. [Abstract] [Full-text]
79. Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients.
    Neurobiol Aging, 26(6): 789-94. [Abstract] [Full-text]
80. Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42.
    Neurobiol Aging, 26(6): 785-8. [Abstract] [Full-text]
81. Novel therapeutic strategies for Alzheimer's disease based on the forgotten reproductive hormones.
    Cell Mol Life Sci, 62(3): 313-9. [Abstract] [Full-text]
82. Evidence for the role of gonadotropin hormones in the development of Alzheimer disease.
    Cell Mol Life Sci, 62(3): 293-8. [Abstract] [Full-text]
83. Androgens, andropause and neurodegeneration: exploring the link between steroidogenesis, androgens and Alzheimer's disease.
    Cell Mol Life Sci, 62(3): 281-92. [Abstract] [Full-text]
84. Alzheimer's associated inflammation, potential drug targets and future therapies.
    J Neural Transm, 112(3): 429-53. [Abstract] [Full-text]
85. ACE I/D polymorphism is a risk factor of Alzheimer's disease but not of vascular dementia.
    Neurosci Lett, 377(1): 37-9. [Abstract] [Full-text]
86. Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations.
    Free Radic Biol Med, 38(6): 746-54. [Abstract] [Full-text]
87. Biphenyls labeled with technetium 99m for imaging beta-amyloid plaques in the brain.
    Nucl Med Biol, 32(2): 171-84. [Abstract] [Full-text]
88. Solution structure of humanin, a peptide against Alzheimer's disease-related neurotoxicity.
    Biochem Biophys Res Commun, 329(1): 152-60. [Abstract] [Full-text]
89. Evidence for increased lysyl oxidase, the extracellular matrix-forming enzyme, in Alzheimer's disease brain.
    Neurosci Lett, 376(3): 210-4. [Abstract] [Full-text]
90. Semantic relevance best predicts normal and abnormal name retrieval.
    Neuropsychologia, 43(5): 754-70. [Abstract] [Full-text]
91. EEG filtering based on blind source separation (BSS) for early detection of Alzheimer's disease.
    Clin Neurophysiol, 116(3): 729-37. [Abstract] [Full-text]
92. Disturbed fluctuations of resting state EEG synchronization in Alzheimer's disease.
    Clin Neurophysiol, 116(3): 708-15. [Abstract] [Full-text]
93. Synaptic transmission and synchronous activity is disrupted in hippocampal slices taken from aged TAS10 mice.
    Hippocampus, 15(1): 110-7. [Abstract] [Full-text]
94. The human pineal gland and melatonin in aging and Alzheimer's disease.
    J Pineal Res, 38(3): 145-52. [Abstract] [Full-text]
95. Gender differences in glutathione metabolism in Alzheimer's disease.
    J Neurosci Res, 79(6): 861-7. [Abstract] [Full-text]
96. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
    J Neurosci, 25(8): 1904-13. [Abstract] [Full-text]
97. Cystatin C as a risk factor for Alzheimer disease.
    Neurology, 64(4): 755-7. [Abstract] [Full-text]
98. Unawareness of cognitive deficit (cognitive anosognosia) in probable AD and control subjects.
    Neurology, 64(4): 693-9. [Abstract] [Full-text]
99. Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease.
    Magn Reson Med, 53(3): 607-13. [Abstract] [Full-text]
100. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease.
     Proc Natl Acad Sci U S A, 102(8): 3046-51. [Abstract] [Full-text]
101. Mitogen- and stress-activated protein kinase 1: convergence of the ERK and p38 pathways in Alzheimer's disease.
     J Neurosci Res, 79(4): 554-60. [Abstract] [Full-text]
102. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease.
     Science, 307(5713): 1282-8. [Abstract] [Full-text]
103. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience.
     Radiology, 234(3): 851-9. [Abstract] [Full-text]
104. The future of aging therapies.
     Cell, 120(4): 557-67. [Abstract] [Full-text]
105. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective.
     Cell, 120(4): 545-55. [Abstract] [Full-text]
106. Atlas-guided non-uniform attenuation correction in cerebral 3D PET imaging.
     Neuroimage, 25(1): 278-86. [Abstract] [Full-text]
107. Verbal episodic memory impairment in Alzheimer's disease: a combined structural and functional MRI study.
     Neuroimage, 25(1): 253-66. [Abstract] [Full-text]
108. Fractional Gaussian noise, functional MRI and Alzheimer's disease.
     Neuroimage, 25(1): 141-58. [Abstract] [Full-text]
109. The "promiscuous drug concept" with applications to Alzheimer's disease.
     FEBS Lett, 579(6): 1338-42. [Abstract] [Full-text]
110. The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide.
     Eur J Neurosci, 21(3): 733-40. [Abstract] [Full-text]
111. Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils.
     J Biol Chem, 280(9): 7677-84. [Abstract] [Full-text]

© 2004-2008 Alzheimer's Disease Research Today. All Rights Reserved.